Dobek Maria 4
4 · Janux Therapeutics, Inc. · Filed Jan 2, 2026
Insider Transaction Report
Form 4
Dobek Maria
Vice President, Accounting
Transactions
- Sale
Common Stock
2026-01-02$13.73/sh−1,462$20,073→ 15,373 total - Award
Common Stock
2026-01-02+18,935→ 34,308 total - Award
Stock option (right to buy)
2026-01-02+42,600→ 42,600 totalExercise: $13.65Exp: 2036-01-01→ Common Stock (42,600 underlying)
Footnotes (4)
- [F1]The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- [F2]Includes 2,834 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2025.
- [F3]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
- [F4]25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.